VB119

DRUG2 trials

Sponsors

Tenet Medicines

Conditions

Focal Segmental GlomerulosclerosisMembranous NephropathyMinimal Change Disease

Phase 1

Efficacy and Safety of VB119 in Subjects With Membranous Nephropathy

TerminatedNCT04652570

Tenet MedicinesMembranous Nephropathy

Start: 2021-05-05End: 2024-08-15Updated: 2026-02-12

Phase 2

Efficacy and Safety of VB119 in Subjects With Minimal Change Disease (MCD) and Focal Segmental Glomerulosclerosis (FSGS)

TerminatedNCT05441826

Tenet MedicinesFocal Segmental Glomerulosclerosis, Minimal Change Disease

Start: 2022-05-03End: 2023-10-12Updated: 2024-04-22